Advances In The Mechanism And New Therapies Of Alopecia Areata

    October 2023 in “ International journal of rheumatic diseases ”
    Yi Jin, Zhiyong Guo, Weihua Pan, Xiaopan Wang, Qiang Tong
    From the encyclopedia
    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Baricitinib →

    JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

    Image
    Studysummary This study found that the JAK3/TEC kinase inhibitor ritlecitinib was effective and well tolerated in patients aged 12 and older with alopecia areata, providing a potential systemic treatment option for this condition, especially in cases of significant psychosocial impact. Our plain-language summary of this paper — not a Tressless recommendation.
    Alopecia areata (AA) is a T-cell mediated hair loss condition with an immunoinflammatory basis, affecting about 2% of the global population. Current treatments are limited and often ineffective, especially for severe cases. Recent advances have identified Janus kinase (JAK) inhibitors as promising therapies. Baricitinib, a JAK1/2 inhibitor, is the only FDA-approved treatment for severe AA in adults. A phase 2b–3 trial showed that ritlecitinib, a JAK3/TEC kinase inhibitor, is effective and well-tolerated in patients aged 12 and older. Other JAK inhibitors like deuruxolitinib and ruxolitinib also show potential. The study highlights the need for continued research into targeted therapies to address the significant unmet needs in AA treatment, particularly for adolescents and those with severe disease.
    Discuss this study in the Community →

    Research cited in this study

    14 / 14 results